Healthcare with Confidence
Immune therapy for brain cancer offers promising options for treating tumors that have traditionally been managed with surgery, radiotherapy, and chemotherapy.
Brain tumors occur in both children and adults and include many different diagnoses.
Glioblastoma (GBM) is the most aggressive and fast-growing primary brain tumor in adults.
Cancer immunotherapy in Israel aims to stimulate or direct the immune system so the body can recognize and attack cancer cells. In some situations it can be used instead of chemotherapy, but more often it is used in combination with standard treatments—or through clinical trials, especially for glioblastoma.
What is immunotherapy (in simple terms)?
Immunotherapy is a group of treatments that help the immune system find and destroy cancer cells. The most widely used immunotherapy medicines today are immune checkpoint inhibitors, which block “checkpoint” signals that can prevent T-cells from attacking cancer—effectively helping the immune system “take the brakes off.”
Why brain tumors are different (the blood-brain barrier)
The brain is protected by the blood–brain barrier (BBB), which limits what substances—including medicines—can enter brain tissue. This is one reason drug therapy can be challenging in brain tumors. Surgery and radiation are not limited by BBB in the same way, but many medicines must still reach the tumor to work well.
Brain cancer immunotherapy in Israel: what’s actually used today
Israel’s major oncology centers follow international evidence-based protocols, and patients may access immunotherapy when it is proven effective for their diagnosis, or within clinical trials.
Checkpoint inhibitors (PD-1 / PD-L1 / CTLA-4)
Checkpoint inhibitors are widely used in many cancers and are being studied in brain tumors. For glioblastoma, results to date have been mixed, so checkpoint inhibitors are typically considered in selected situations and clinical trials, rather than routine “standard for everyone.”
Where they matter most in “brain cancer” today:
For brain metastases (cancer that spread to the brain), immunotherapy can be a major part of treatment for certain cancers—especially melanoma. Long-term data continue to support the benefit of ipilimumab + nivolumab in melanoma brain metastases.
Cellular immunotherapy (CAR-T and related therapies)
CAR-T is an advanced immune cell therapy already established for some blood cancers, and next-generation CAR-T approaches are actively being studied for glioblastoma in clinical research.
Vaccines, oncolytic viruses, and next-generation immune approaches (mostly via trials)
There are ongoing clinical efforts worldwide (and trials accessible through Israeli centers depending on eligibility) studying:
- Cancer vaccines
- Oncolytic viruses (viruses designed to infect tumor cells and trigger immune responses)
- Combination immune strategies
Important note: Avastin® and Unituxin® (updated + clarified)
- Avastin® (bevacizumab) is an anti-VEGF targeted antibody that disrupts tumor blood vessel growth. It received FDA accelerated approval in May 2009 for recurrent glioblastoma (tumor progression after prior therapy). It is widely considered a biologic/targeted option rather than classic immune-activating immunotherapy.
- Unituxin® (dinutuximab) is an antibody immunotherapy approved for high-risk neuroblastoma in children. Neuroblastoma is a tumor of the nervous system but usually does not start in the brain (it often arises outside the brain).
Precision (personalized) treatment: why it matters for brain tumors
Because not every patient responds the same way, Israeli teams often emphasize molecular and genomic profiling to personalize treatment and to identify trial options.
For brain tumors, doctors commonly use tumor-specific molecular markers (depending on diagnosis) and may recommend broader profiling when standard options are limited or when the tumor recurs. Research groups at major Israeli centers also focus on the unique immunology of brain tumors to translate findings into clinical investigations.
When molecular testing is especially important
- If the tumor is not responding to the current protocol
- Relapse / progression after initial treatment
- Rare tumor types or unclear pathology
- Patients seeking advanced options beyond standard therapy
Side effects: what patients should know (realistic + reassuring)
Immunotherapy side effects are often different from chemotherapy. Many patients feel well, but some develop immune-related inflammation that can affect:
- Skin (rash, itching)
- Thyroid/hormones (fatigue, weight changes)
- Gut (diarrhea/colitis)
- Liver (hepatitis—sometimes only seen on labs)
- Lungs (new cough/shortness of breath)
Rule: report new symptoms early—many immune side effects are manageable when treated promptly.
How international patients start immunotherapy-focused brain tumor care in Israel
Many patients begin with an online consultation / second opinion before traveling. A typical plan includes:
- Expert review of pathology + imaging
- A biomarker checklist (what’s done, what’s missing)
- A clear written strategy: standard options + trial options
- Coordination at a major center and follow-up planning
What to send for a second opinion
- Pathology report (and molecular results if available)
- Imaging reports: MRI brain, ± CT/PET-CT (plus scan files if possible)
- Treatment summary (surgery / radiation / drugs, dates, response, side effects)
- Current symptoms + medication list
Want a clear, personalized plan from an Israeli brain tumor team—focused on modern immunotherapy and precision options?
⇒ Consult with Top Brain Cancer Specialist
⇒ Consult with Top Neurosurgeon
- Cancer Immunotherapy in Israel (Online Consultation / Second Opinion)
- Molecular genomic tests for precision cancer treatment in Israel
- Precision cancer treatment in Israel
- Cancer Pre-Screening Online in Israel
